[Meta] the state board rule is doing its job and people should stop complaining
the state board rule is doing its job and people should stop complaining. Short post, long comment section, probably.
Paid noticeably more at one clinic than another for what turned out to be the same facility behind both.
The five questions worth asking before you commit to any compounded arrangement.
Which facility, by name. Whether it is a 503A pharmacy or a 503B outsourcing facility. What concentration is on the label. What the beyond-use date is based on. Whether there is potency testing on the finished preparation rather than only on the starting material.
All five are answerable in one email and the pattern of what comes back is more informative than any of the individual answers. An organisation with a quality system finds these questions ordinary.
Asked for potency testing on the finished preparation. They had it. I had assumed they would not.
Screenshot none of this. Read the whole thread, including the parts where I am told I am wrong.
best — the order this archive was captured in
Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.
Reminder that nothing here is medical advice and this board cannot tell you which arrangement to choose.
[deleted]
Correction: patient-specific refers to the prescription, not to a bespoke formulation. Common misreading and it changes the argument.
the shortage list is the whole legal hinge and people skip it
What did the intake actually ask you?
Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.
Who is the prescriber, and are they the same organisation as the pharmacy?
Small fix — 503B facilities register with the regulator; 503A pharmacies are licensed by the state board. Different mechanisms.
The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.
if a clinic will not name the facility, that is your answer
Agreed. The 503A versus 503B distinction changes who is allowed to make what, and almost every confused thread here starts by ignoring it.
What concentration is on the label, and does it match what you were expecting?
Yes. The shortage list is the legal hinge for the whole arrangement and its status is public.
Kept the label from every vial. When the shortage status changed, having the paper trail made the conversation much shorter.
Agreed on potency testing of the finished preparation. That is a different question from the purity of the starting material.
A beyond-use date derived from published stability data means something different from one assigned by default rule. Asking which is a fair question and the answer is usually available.
Correcting my own comment: the shortage status changed in the interim, so the arrangement I described no longer applies.
Switched between two compounded preparations and the concentration on the label was different. Redid the arithmetic on paper before drawing anything.
Asked for the beyond-use date basis and got a real answer with a stability reference attached. Not universal, apparently.
Cosigning the beyond-use date question. What it is based on tells you whether anybody has done stability work.
503A is patient-specific, 503B is outsourcing facility, they are not the same thing
Concentration on the compounded vial was different from what I had been using and I nearly did the arithmetic on autopilot.
a 503B has to register and report, so there is a paper trail to ask for
- 1What did the intake actually ask you?6 comments in this branch · started by u/ireland_drugs_pay